Open AccessThe Brazilian experience of implementing the active pharmacovigilance of dolutegravir
Author(s) -
Cynthia Julia Braga Batista,
Renato Girade Corrêa,
Livia Ramalho Evangelista,
Karen Fleck,
Leandro Silva,
Françoise Renaud,
Marco Vitória,
Meg Doherty,
Adèle Schwartz Benzaken
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000014828
Subject(s) - pharmacovigilance , medicine , dolutegravir , tolerability , adverse effect , nausea , expanded access , drug reaction , christian ministry , pediatrics , family medicine , pharmacology , drug , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , philosophy , theology
Abstract In 2017, the Ministry of Health Brazilian started using dolutegravir (DTG) 50 mg to all people living with HIV who began antiretroviral therapy (ART) or rescue regimens. Although DTG is thought to have better tolerability levels and a lower possibility of causing adverse reactions, it is necessary to continuously evaluate the safety profile of the drug in the population. Therefore, an active pharmacovigilance project for DTG was implemented. The objective of this study was to describe the Brazilian experience of implementing pharmacovigilance and the results obtained during the period between April and December 2017. Active pharmacovigilance was implemented through patient interviews and an online questionnaire developed in the Medication Logistics Control System (SICLOM). Of the total number of people on DTG in Brazil (79,742) 90.33% participated in the project, and 2.24% of those who participated reported adverse reactions to the drug; of those who reported adverse reactions, 73.86% were on first-line ART regimens, and 26.13% were on third-line regimens. The mean age of the patients who had adverse reactions to DTG was 39 years; 68.79% were male, and 31.21% were female. Of the adverse reactions reported, 50.39% were considered persistent. The 3 most frequent reactions were nausea (13.34%), diarrhea (9.83%), and headaches (9.23%). The Brazilian experience with this project has been deemed successful by federal and local managers, and the online tool to collect data has proved to be an important strategy for the pharmacovigilance of DTG as well as that of other drugs.